Abnormal aggregation and increased size of platelets in myeloproliferative disorders
Related Experiment Videos
Abstract:
Platelet aggregation is frequently impaired in myeloproliferative disorders (MPD). The presence of spontaneous platelet aggregation (SPA) or alterations of the aggregation pattern after ADP, epinephrine and collagen have been a frequent feature in the series of 52 patients here presented. The occurrence of SPA was not related to the findings obtained with the aggregating agents or to the number of circulating platelets. The aggregation results did not correlate with the number of megathrombocytes. The presence of platelet abnormalities, not completely corrected after busulfan therapy, and the increased size of platelets should aid in diagnosis of myeloproliferative disorders.
Insights
Platelet aggregation abnormalities, including spontaneous platelet aggregation (SPA), are common in myeloproliferative disorders (MPD). These platelet changes can aid in MPD diagnosis, even after treatment.
Area of Science:
- Hematology
- Oncology
- Clinical Pathology
Background:
- Platelet aggregation is often abnormal in patients with myeloproliferative disorders (MPD).
- Spontaneous platelet aggregation (SPA) and altered responses to agonists are frequently observed in MPD patients.
Purpose of the Study:
- To investigate the diagnostic utility of platelet aggregation patterns in myeloproliferative disorders.
- To assess the relationship between platelet aggregation, SPA, and other clinical parameters in MPD.
Main Methods:
- Evaluated platelet aggregation patterns in 52 patients with myeloproliferative disorders.
- Assessed responses to adenosine diphosphate (ADP), epinephrine, and collagen.
- Correlated aggregation findings with the presence of SPA, platelet count, and megathrombocyte count.
Main Results:
- SPA and altered aggregation patterns were frequent findings in the patient cohort.
- SPA occurrence did not correlate with responses to aggregating agents or platelet/megathrombocyte counts.
- Platelet abnormalities persisted post-busulfan therapy and were associated with increased platelet size.
Conclusions:
- Platelet aggregation abnormalities, including SPA and increased platelet size, are characteristic of MPD.
- These platelet findings can assist in the diagnosis of myeloproliferative disorders.
- Persistent platelet abnormalities after therapy suggest their value in ongoing disease assessment.